Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish pharmaceutical company Meda has agreed to acquire ten products from Wyeth for approximately $3.7 million.
Subscribe to our email newsletter
The acquired portfolio include CNS drug Seresta, an anti-anxiety agent used for sleep disorders and substance-withdrawal symptoms. No employees will transfer from Wyeth to Meda in conjunction with the acquisition, which is expected to inject sales of about $24-25 million into Meda’s operation for the remainder of 2007.
Meda said that the deal strengthens its position on two of its most important markets: Italy and France. These countries account for about 60% of the acquired products’ sales.